(MENAFN- PR Newswire)
DUBLIN, Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it will report second quarter 2022 earnings results for the period ended July 1, 2022, on Thursday, August. 11, 2022.
A conference call for investors will begin at 8:30 a.m. ET. The call can be accessed as follows:
- Directly via the webcast link (live and replay):
- At the Mallinckrodt website:
ABOUT MALLINCKRODT Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit .
Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.
CONTACTS
Investor Relations Daniel SpecialeGlobal Corporate Controller & Chief Investor Relations Officer314-654-3638[email protected]
Derek BelzVice President, Investor Relations314-654-3950[email protected]
Media Michael Freitag / Aaron Palash / Aura ReinhardJoele Frank, Wilkinson Brimmer Katcher212-355-4449
Mallinckrodt, the 'M' brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2022 Mallinckrodt.US-2200293 08/22
SOURCE Mallinckrodt Pharmaceuticals
MENAFN03082022003732001241ID1104639078
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.